Skip to Content Skip to Search

Asset reunification - ProSearch

We run a tracing programme in partnership with ProSearch, with the aim of reuniting 'lost' shareholders or their estates with unclaimed cash entitlements in respect of payments made by GSK, Glaxo Wellcome or SmithKline Beecham.

There are various reasons why cash entitlements may not have been claimed by shareholders.

The most common reasons are:

  • Shareholder not notifying the registrar of a change of address; or
  • Where a shareholder has deceased and the beneficiaries or executors of an estate are not aware of the holding.

If you would like to clarify whether you or a deceased person for whose estate you act holds shares in GSK (or held shares in Glaxo Wellcome or SmithKline Beecham), please contact our registrar, Equiniti Limited (‘Equiniti’) for further assistance. Find how to contact on the Investors contact details.

ProSearch FAQs

Who is ProSearch?

ProSearch Asset Solutions Limited ('ProSearch') is a subsidiary of Equiniti and specialises in the research, identification and the reuniting of unclaimed assets with their owners or next of kin.

They have worked with a variety of well-known companies on similar projects. For more information, please visit ProSearch website.

Back to top

Why is this entitlement due?

Cheques have been issued that may have been returned to Equiniti undelivered and/or remain uncashed. These may be in respect of dividends paid either by GSK, Glaxo Wellcome or SmithKline Beecham and may also include payments issued pursuant to corporate actions such as special dividends.

GSK have instructed ProSearch to try to find and assist those shareholders or their legal representatives with the repatriation of unclaimed amounts to which they may be entitled.

Back to top

What should you do if you have received a claim form?

ProSearch will only send a claim form to an address at which they are reasonably certain the shareholder, or their legal representative, resides in.

The claim form is designed to make the recovery of entitlements as easy as possible. To use this voluntary service, please follow the instructions provided and return the signed and dated form (along with any necessary documents) to ProSearch in the pre-paid envelope provided.

Back to top

Why is there a fee for using this service?

In the process of operating a programme to trace lost shareholders, ProSearch incurs costs including data subject analysis, mailings, identity confirmation, claim validation, and a helpline.

The ProSearch service is voluntary. Should you choose to use this voluntary service there will be a fee of 12.5%, plus VAT, of the cash entitlement due. In addition, where a valid share certificate for your holding is not returned with your claim form, ProSearch will charge an administration fee of 12.5% of the share value recovered (plus VAT), together with a lost certificate charge of 2% (plus VAT) of the value of shares reissued. ProSearch will deduct all fees from the entitlements recovered.

Alternatively, you may make your own arrangements to recover your entitlements by contacting Equiniti directly. Find how to contact on the Investors contact details.

Back to top

How to contact ProSearch?

You can call them on 0371 384 2832 from within the UK (+44 371 384 2832 if calling from outside the UK).

The lines are open from 8.30am to 5.30pm Monday to Friday (excluding UK Bank Holidays).

Back to top

How to get further information about unclaimed entitlements or shares?

Please contact Equiniti for further information. Find how to contact on our Investors contact details page.

Back to top

Arrange Direct Dividend Payments

In January 2020, GSK made the decision to no longer pay dividends by cheque and instead issue dividend payments by direct credit into shareholders’ nominated bank accounts. This is a more efficient, secure and environmentally-friendly method of payment.


There are a number of ways you can register your bank details with Equiniti to set up direct payments:


For more information on mandated direct credit, please see our FAQs.

Back to top

Back to top